A Proven Combination for AAV Production
Transfection Reagent & Chemically Defined HEK Media Bundle
Overview
Viral vector-based therapeutics address a broader
spectrum of indications, moving away from ultrarare diseases.
Therefore, drug developers and manufacturers increasingly
seek robust, scalable, and standardized platforms.

Key Viral Vectors Production
Challenges--

High manufacturing process variability
Media and transfection reagent combinationmust be optimized
Selecting the right formulations is timeand cost intensive

Standard, Matching
Formulations From Transient
Transfection up to Infection----

HEK TF | Most established medium
HEK ViP NB | Leanest transfection medium
HEK ViP NX | Highest nutrient-containing medium
HEK-FS_2 | Unique feeding solution
FectoVIR®-AAV | Transfection reagent designed
for improved AAV titers

Combining key and high performing raw materials such as
FectoVIR®-AAV, a novel generation of synthetic transfection
reagents, and chemically defined HEK media addresscommercial scale challenges including reproducibility andcost optimization.

Genomic titer [vg/L]

1.40+14

1.3E+141.2E+14

1.20+141.00+148.00+13

7.1E+136.00+134.00+13

AAV-2 Production in VPC 2.0 HEK Cells in Ambr® 15Bioreactors With FectoVIR®-AAV Reagent

Genomic titer [vg/L]

Comparison of AAV Yields Using FectoVIR®-AAVand HEK Media

1.40E+14
1.20E+141.00E+148.00E+136.00E+134.00E+132.00E+130.00E+00

2.00+13Competitor media 1

Competitor media 2

HEK ViP NB

Competitor media 1

Competitor media 2

HEK ViP NB

0.00+00
Expi293F™ in
HEK ViP NB

Expi293F™ in
HEK TF

1.4E+14

Genomic titer [vg/L]

1.40+14
1.20+141.00+148.8E+138.00+13

Capsid titer [vp/L]

Expi293F™ incompetitor media

3.50E+153.00E+152.50E+152.00E+151.50E+151.00E+155.00E+140.00E+00

6.00+134.00+13Figure 3: HEK ViP NB media achieves comparable AAV-2 genomictiters and as reproducible capsid titers than industry reference media

2.6E+132.00+130.00+00
Freestyle™ 293-F incompetitor media

Freestyle™ 293-F
in HEK ViP NB

Freestyle™ 293-F
in HEK TF

Relataive AAV-2 genomic titer

Figure 1: Genomic titers in a shake flask process. AAV-2 production
in Expi293F ™ and Freestyle™ 293-F cells using HEK ViP NB andHEK TF compared with a commercially available competitor medium. Transfection (TF) was done using FectoVIR®-AAV and atwo-plasmid system

877.3654321101.61FreeStyle™ 293-F

Expi293F™

Transfected with competitor reagent

Transfected with FectoVIR®-AAV

Figure 2: Comparison of AAV-2 titers in cell lysate for commercialsuspension HEK cell lines in HEK ViP NX medium using different
transfection reagents according to manufacturer’s protocols.
Titers were measured via qPCR

ItemHEK293 Media and Feed FS_2 Kit1FectoVIR®-AAV2

1Compared to typical media development or benchmarking,our customers have reportedly cut media selection time byhalf, from 12+ months to less than 6 months thanks to ouroff-the-shelf HEK media kit.
AAV-2 titers increased by 2 to 5-fold when coupling
FectoVIR®-AAV transfection reagent with HEK ViP NB media
in both Expi293F™ and FreeStyle™ 293-F reference cell lines[Figure 1]. Similarly, the combination of FectoVIR®-AAV andHEK ViP NX media resulted in a 7-fold rise in AAV-2 titers[Figure 2] versus the industry standard transfection reagent.
Bundled together, our chemically defined HEK media,
manufactured under ISO9001 and ISO13485 referential,and FectoVIR®-AAV transfection reagent, manufactured incompliance with ICH Q7 GMP guidelines, set a benchmark
towards a robust and reproducible approach for viral-vector
processes.
Order your media sample kit here:
www.sartorius.com/cell-culture-media-sample

Order Information

FectoVIR®-AAV

Summary2

Description

Details

Order Number

Select the best fit media and feed for the application

5 × 1 L bottle

CFV3FB4001 | SartoriusTransfection reagent for rAAV production in bothsuspension and adherent HEK293 cells

1 mL vial

101000044 | Polyplus

10 mL bottle

101000022 | Polyplus

Other volumes, formats, and packaging available 2 Other volumes, packaging, and GMP grade available

Specifications subject to change without notice.
© 2024 Copyright Sartorius Stedim Biotech
GmbH, August-Spindler-Strasse 11,37079 Goettingen, Germany
Status: 02 | 2024F or more information, visit
www.sartorius.com | www.polyplus-sartorius.com